Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced positive topline results from its pivotal Phase 3 APPROACH trial evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study enrolled 222 participants and achieved statistically significant improvements across its primary, key secondary, and other secondary endpoints, according to the company's press release.
The results carry substantial implications for the millions of people living with MDD, a condition that often resists standard treatments. At the primary six-week endpoint, HLP003 produced a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS), compared with 11.9 points for placebo, representing a 7.6-point difference (p<0.0001). Significant improvements were observed as early as Day 2, with treatment benefits maintained through Week 12, when the placebo-adjusted difference was 7.0 points (p<0.0001). HLP003 also demonstrated statistically significant improvements in response and remission rates, with 50.9% of treated participants achieving remission at Week 6 compared with 18.2% receiving placebo.
The treatment was generally well tolerated, with most adverse events mild to moderate and transient, although three treatment-related serious adverse events were reported. No new safety signals were identified. APPROACH is the first of three studies in the company's PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027 as it advances HLP003 toward potential regulatory approval and commercialization.
For patients and clinicians, these findings suggest a potential new adjunctive therapy that acts rapidly and sustains benefit, a notable contrast to many existing antidepressants that can take weeks to show effect. Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address a serious condition with limited treatment options. The company is also developing HLP004 in Phase 2 for generalized anxiety disorder and operates in Canada, the United States, the United Kingdom, and Ireland. For more details, the full press release is available at https://ibn.fm/IloYS, and company updates can be found at www.helus.com.
The announcement was disseminated through NetworkNewsWire, a communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers services including InvestorWire wire solutions and editorial syndication to 5,000+ outlets. For full terms and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.

